发明名称 |
Injectable preparations of diclofenac and its pharmaceutically acceptable salts |
摘要 |
Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. |
申请公布号 |
US9211251(B2) |
申请公布日期 |
2015.12.15 |
申请号 |
US201313749872 |
申请日期 |
2013.01.25 |
申请人 |
TROIKAA PHARMACEUTICALS LIMITED |
发明人 |
Patel Ketan Rajnibhai;Patel Milan Rajnibhai |
分类号 |
A61K31/195;A61K9/00;A61K47/10;A61K31/196 |
主分类号 |
A61K31/195 |
代理机构 |
Baker Hostetler LLP |
代理人 |
Baker Hostetler LLP ;Patel, Esq. Tayan B. |
主权项 |
1. An injectable preparation comprising:
(A) at least one water-soluble salt of diclofenac (75 mg); (B) a single co-solvent selected from the group consisting of:
a monohydric alcohol (4% to 25% v/v) selected from the group consisting of benzyl alcohol and ethyl alcohol,a polyhydric alcohol (27% to 45% v/v) selected from the group consisting of propylene glycol, polyethylene glycols having a molecular weight of between 300 to 600 Dalton, glycerin, and 1,3-butylene glycol, andglycofurol (18% to 35% v/v),in combination with water; (C) an alkali selected from the group consisting of sodium hydroxide and potassium hydroxide; and (D) a buffer system selected from the group consisting of phosphate buffer and bicarbonate buffer; wherein the viscosity of the preparation ranges from 1.50 to 4.7 centipoise (CPS); the final volume of the injectable solution is approximately 1 ml; the pH of the injectable solution is maintained at between 8 and 9 by said alkali and said buffer system; and the injectable solution is capable of being administered by the intradeltoid, intragluteal route, and/or slow intravenous route. |
地址 |
Gujarat IN |